Drew Dykes, APRN
Psychiatric/Mental Health · Baton Rouge, LANPI 1033779087
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 584 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 584 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Indivior Inc.$926
- AbbVie$770
- plus $3K from 10 others
What the payments were for
- Food & beverage$10,60498%
- Education$2542%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 90 | $2,275 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 89 | $1,332 |
| Alkermes, Inc. | 70 | $1,195 |
| Neurocrine Biosciences, Inc. | 49 | $1,114 |
| Indivior Inc. | 50 | $926 |
| AbbVie | 51 | $770 |
| Johnson & Johnson | 43 | $703 |
| Otsuka America Pharmaceutical, Inc. | 47 | $673 |
| Axsome Therapeutics, Inc. | 18 | $544 |
| Vanda Pharmaceuticals Inc. | 24 | $485 |
| Lundbeck LLC | 27 | $371 |
| E.r. Squibb & Sons, L.L.C. | 13 | $248 |
| Sunovion Pharmaceuticals Inc. | 7 | $107 |
| Braeburn Inc. | 3 | $68 |
| Luye Pharma (USA) Ltd. | 2 | $28 |
| Noven Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$122
- Auvelity$121
How this compares
$10,859 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 116 | $358,074 |
| Austedo XrDeutetrabenazine | 15 | $238,945 |
| Invega TrinzaPaliperidone Palmitate | 18 | $114,039 |
| AristadaAripiprazole Lauroxil | 22 | $77,715 |
| UzedyRisperidone | 11 | $58,854 |
| Risperdal ConstaRisperidone Microspheres | 21 | $41,900 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $7,274 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 41 | $6,018 |
| Quetiapine Fumarate | 292 | $5,528 |
| Divalproex Sodium ErDivalproex Sodium | 121 | $5,063 |
| Aripiprazole | 123 | $4,440 |
| Trazodone Hcl | 270 | $4,394 |
| Olanzapine | 196 | $3,866 |
| Oxcarbazepine | 105 | $3,350 |
| Buspirone Hcl | 169 | $2,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $703 | $514,012155 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $2,275 | $297,79926 claims |
| Alkermes, Inc.Aristada | $1,195 | $77,71522 claims |
| Indivior Inc.Suboxone | $926 | $7,27413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Baton Rouge
- Amy LacoutureBaton Rouge$663K
- Yolanda CockerhamBaton Rouge$11K
- Tiffany JordanBaton Rouge$10K
- Elizabeth CasselberryBaton Rouge$9K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.